- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00227253
Chromosome 18 Clinical Research Center (Chromosome18)
The Chromosome 18 Clinical Research Center
Study Overview
Status
Intervention / Treatment
- Procedure: Determination of growth hormone status
- Procedure: Measurement of growth, thyroid and sex hormone levels
- Procedure: Behavior and neuropsychometric evaluations
- Procedure: Audiological and ear, nose and throat examination
- Procedure: Magnetic resonance imaging of the brain
- Procedure: Dysmorphology evaluation
- Procedure: Neurology examination
- Procedure: Dental evaluation
- Procedure: Speech pathology evaluation
- Procedure: Psychiatric evaluation
- Procedure: Orthopedic evaluation
- Procedure: Ophthalmologic evaluation
- Procedure: Gastrointestinal evaluation
Detailed Description
Protocol Summary:
The hypotheses are:
- growth hormone (GH) deficiency in children with chromosome 18 deletions is accompanied by cognitive and microstructural abnormalities of the brain that can be ameliorated by GH treatment; and
- the physical and behavioral findings in individuals with abnormalities of chromosome 18 are due to the genes that present in a non-diploid number.
Therefore, correlation of the physical and behavioral findings with the extent of the deletion will help identify the genes involved. An understanding of the molecular mechanisms of the phenotype will provide the insight necessary to devise appropriate therapies.
Our goals are:
- to be the international medical and education resource for the families of individuals with chromosome 18 abnormalities;
- to perform and facilitate both clinical and basic research relating to the disorders of chromosome 18; and
- to devise treatments to help these individuals overcome the negative effects of their chromosome abnormality.
To attain these goals, the study has the following specific aims:
- perform genotypic molecular analysis on the DNA of the subjects and their biological parents to determine the genotype of the affected individual;
gather comprehensive clinical data on individuals with chromosome 18 abnormalities including:
- determination of growth hormone levels;
- measurement of corticotrophin, thyroid and sex hormones;
- psychiatric and neuropsychological evaluations;
- audiology and ENT testing;
- brain MRI scan;
- genetic dysmorphology examination;
- neurology exam;
- dental exam;
- speech pathology evaluation;
- gastrointestinal exam;
- orthopedic exam;
- ophthalmology exam.
The phenotypical assessment will be longitudinal; therefore, the participants will have a wide age range. This extensive range plus the fact that some participants will be assessed multiple times means that not all components of the clinical studies will be appropriate for every subject at every visit.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jannine D. Cody, Ph.D.
- Phone Number: 210-567-9220
- Email: cody@uthscsa.edu
Study Contact Backup
- Name: Daniel E. Hale, M.D.
- Phone Number: 210-567-5284
- Email: hale@uthscsa.edu
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- University Health Systems Hospital
-
Contact:
- Janinne Cody, PhD
- Phone Number: 210-567-9220
- Email: cody@uthscsa.edu
-
San Antonio, Texas, United States, 78229
- Recruiting
- University of Texas Health Science Center at San Antonio
-
Contact:
- Jannine D Cody, Ph.D.
- Phone Number: 210-567-9220
- Email: cody@uthscsa.edu
-
Contact:
- Daniel E Hale, M.D.
- Phone Number: 210-567-5284
- Email: hale@uthscsa.edu
-
Principal Investigator:
- Jannine D. Cody, Ph.D.
-
Sub-Investigator:
- Peter T. Fox, M.D.
-
Principal Investigator:
- Daniel E. Hale, M.D.
-
Sub-Investigator:
- Brian P Perry, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Must have a confirmed diagnosis of Chromosome 18 or be the parent/guardian of a child with Chromosome 18
- Subject must be at least one year of age to participate in the clinical examination aspect of the study (due to issues of venous access and blood volume required to complete studies)
- General health status: good
Description
Inclusion Criteria:
- Must have a confirmed diagnosis of Chromosome 18 or be the parent/guardian of a child with Chromosome 18
- Subject must be at least one year of age to participate in the clinical examination aspect of the study (due to issues of venous access and blood volume required to complete studies)
- General health status: good
Exclusion Criteria:
- Pregnant women
- Dead fetuses
- Prisoners
- Non-viable neonates or neonates of uncertain viability
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary
Time Frame: Ongoing
|
Provide definitive medical and education resources for the families of individuals with chromosome 18 abnormalities
|
Ongoing
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel E. Hale, M.D., The University of Texas Health Science Center at San Antonio
- Principal Investigator: Jannine D. Cody, Ph.D., The University of Texas Health Science Center at San Antonio
Publications and helpful links
General Publications
- Cody JD, Semrud-Clikeman M, Hardies LJ, Lancaster J, Ghidoni PD, Schaub RL, Thompson NM, Wells L, Cornell JE, Love TM, Fox PT, Leach RJ, Kaye CI, Hale DE. Growth hormone benefits children with 18q deletions. Am J Med Genet A. 2005 Aug 15;137(1):9-15. doi: 10.1002/ajmg.a.30848.
- Lancaster JL, Cody JD, Andrews T, Hardies LJ, Hale DE, Fox PT. Myelination in children with partial deletions of chromosome 18q. AJNR Am J Neuroradiol. 2005 Mar;26(3):447-54.
- Kochunov P, Lancaster J, Hardies J, Thompson PM, Woods RP, Cody JD, Hale DE, Laird A, Fox PT. Mapping structural differences of the corpus callosum in individuals with 18q deletions using targetless regional spatial normalization. Hum Brain Mapp. 2005 Apr;24(4):325-31. doi: 10.1002/hbm.20090.
- Schaub RL, Hale DE, Rose SR, Leach RJ, Cody JD. The spectrum of thyroid abnormalities in individuals with 18q deletions. J Clin Endocrinol Metab. 2005 Apr;90(4):2259-63. doi: 10.1210/jc.2004-1630. Epub 2005 Jan 25.
- Cody JD, Hale DE. Precision in phenotyping and genotyping. Am J Med Genet A. 2004 Dec 15;131(3):313. doi: 10.1002/ajmg.a.30263. No abstract available.
- Gunn SR, Mohammed M, Reveles XT, Viskochil DH, Palumbos JC, Johnson-Pais TL, Hale DE, Lancaster JL, Hardies LJ, Boespflug-Tanguy O, Cody JD, Leach RJ. Molecular characterization of a patient with central nervous system dysmyelination and cryptic unbalanced translocation between chromosomes 4q and 18q. Am J Med Genet A. 2003 Jul 1;120A(1):127-35. doi: 10.1002/ajmg.a.20026.
- Schaub RL, Reveles XT, Baillargeon J, Leach RJ, Cody JD. Molecular characterization of 18p deletions: evidence for a breakpoint cluster. Genet Med. 2002 Jan-Feb;4(1):15-9. doi: 10.1097/00125817-200201000-00003.
- Schaub RL, Cody JD, Hale DE. Growth disorders in the chromosome 18 syndromes. Highlights 9:3-5, 2001
- Hermesch CB, Cody JT, Cody JD. Dental caries history in nine children with chromosome 18p deletion syndrome. Spec Care Dentist. 2000 Mar-Apr;20(2):53-5. doi: 10.1111/j.1754-4505.2000.tb01143.x.
- Hale DE, Cody JD, Baillargeon J, Schaub R, Danney MM, Leach RJ. The spectrum of growth abnormalities in children with 18q deletions. J Clin Endocrinol Metab. 2000 Dec;85(12):4450-4. doi: 10.1210/jcem.85.12.7016.
- Cody JD, Reveles XT, Hale DE, Lehman D, Coon H, Leach RJ. Haplosufficiency of the melancortin-4 receptor gene in individuals with deletions of 18q. Hum Genet. 1999 Nov;105(5):424-7. doi: 10.1007/s004390051125.
- Wang Z, Cody JD, Leach RJ, O'Connell P. Gene expression patterns in cell lines from patients with 18q- syndrome. Hum Genet. 1999 Jun;104(6):467-75. doi: 10.1007/s004390050989.
- Cody JD, Ghidoni PD, DuPont BR, Hale DE, Hilsenbeck SG, Stratton RF, Hoffman DS, Muller S, Schaub RL, Leach RJ, Kaye CI. Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet. 1999 Aug 27;85(5):455-62. doi: 10.1002/(sici)1096-8628(19990827)85:53.0.co;2-z.
- Brkanac Z, Cody JD, Leach RJ, DuPont BR. Identification of cryptic rearrangements in patients with 18q- deletion syndrome. Am J Hum Genet. 1998 Jun;62(6):1500-6. doi: 10.1086/301854.
- Keppler-Noreuil KM, Carroll AJ, Finley SC, Descartes M, Cody JD, DuPont BR, Gay CT, Leach RJ. Chromosome 18q paracentric inversion in a family with mental retardation and hearing loss. Am J Med Genet. 1998 Apr 13;76(5):372-8. doi: 10.1002/(sici)1096-8628(19980413)76:53.0.co;2-p.
- Cody JD, Hale DE, Brkanac Z, Kaye CI, Leach RJ. Growth hormone insufficiency associated with haploinsufficiency at 18q23. Am J Med Genet. 1997 Sep 5;71(4):420-5.
- Gay CT, Hardies LJ, Rauch RA, Lancaster JL, Plaetke R, DuPont BR, Cody JD, Cornell JE, Herndon RC, Ghidoni PD, Schiff JM, Kaye CI, Leach RJ, Fox PT. Magnetic resonance imaging demonstrates incomplete myelination in 18q- syndrome: evidence for myelin basic protein haploinsufficiency. Am J Med Genet. 1997 Jul 25;74(4):422-31. doi: 10.1002/(sici)1096-8628(19970725)74:43.0.co;2-k.
- Cody JD, Pierce JF, Brkanac Z, Plaetke R, Ghidoni PD, Kaye CI, Leach RJ. Preferential loss of the paternal alleles in the 18q- syndrome. Am J Med Genet. 1997 Mar 31;69(3):280-6. doi: 10.1002/(sici)1096-8628(19970331)69:33.0.co;2-n.
- Ghidoni PD, Hale DE, Cody JD, Gay CT, Thompson NM, McClure EB, Danney MM, Leach RJ, Kaye CI. Growth hormone deficiency associated in the 18q deletion syndrome. Am J Med Genet. 1997 Mar 3;69(1):7-12. doi: 10.1002/(sici)1096-8628(19970303)69:13.0.co;2-p.
- Carter E, Heard P, Hasi M, Soileau B, Sebold C, Hale DE, Cody JD. Ring 18 molecular assessment and clinical consequences. Am J Med Genet A. 2015 Jan;167A(1):54-63. doi: 10.1002/ajmg.a.36822. Epub 2014 Oct 22.
- Cody JD, Sebold C, Heard P, Carter E, Soileau B, Hasi-Zogaj M, Hill A, Rupert D, Perry B, O'Donnell L, Gelfond J, Lancaster J, Fox PT, Hale DE. Consequences of chromsome18q deletions. Am J Med Genet C Semin Med Genet. 2015 Sep;169(3):265-80. doi: 10.1002/ajmg.c.31446. Epub 2015 Aug 3.
- Cody JD, Hale DE. Making chromosome abnormalities treatable conditions. Am J Med Genet C Semin Med Genet. 2015 Sep;169(3):209-15. doi: 10.1002/ajmg.c.31447.
- Hasi-Zogaj M, Sebold C, Heard P, Carter E, Soileau B, Hill A, Rupert D, Perry B, Atkinson S, O'Donnell L, Gelfond J, Lancaster J, Fox PT, Hale DE, Cody JD. A review of 18p deletions. Am J Med Genet C Semin Med Genet. 2015 Sep;169(3):251-64. doi: 10.1002/ajmg.c.31445. Epub 2015 Aug 6.
- Sebold C, Soileau B, Heard P, Carter E, O'Donnell L, Hale DE, Cody JD. Whole arm deletions of 18p: medical and developmental effects. Am J Med Genet A. 2015 Feb;167A(2):313-23. doi: 10.1002/ajmg.a.36880. Epub 2015 Jan 14.
- Cody JD, Hasi M, Soileau B, Heard P, Carter E, Sebold C, O'Donnell L, Perry B, Stratton RF, Hale DE. Establishing a reference group for distal 18q-: clinical description and molecular basis. Hum Genet. 2014 Feb;133(2):199-209. doi: 10.1007/s00439-013-1364-6. Epub 2013 Oct 5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Chromosome 18
- 5M01RR001346 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth Hormone Deficiency
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in ChildrenIsrael, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
-
Novo Nordisk A/SWithdrawnGrowth Hormone Disorder | Growth Hormone Deficiency in Children
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
Teva Pharmaceutical Industries, Ltd.TerminatedGrowth Hormone-DeficiencyBelarus, Bulgaria, Georgia, Greece, Hungary, Israel, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine
-
OPKO Health, Inc.CompletedSafety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenPediatric Growth Hormone DeficiencyGreece, Hungary, Slovakia
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Delivery SystemsGermany, Netherlands, Sweden
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
Clinical Trials on Determination of growth hormone status
-
University GhentFund for Scientific Research, Flanders, BelgiumCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedVenous Thromboembolism (VTE)France
-
Artios Pharma LtdCompletedSolid Tumor, Unspecified, AdultUnited States, United Kingdom
-
Osmaniye Korkut Ata UniversityCompleted
-
National Taiwan University HospitalCompletedNeurologic Disorder | Rett Syndrome
-
Universitat Jaume ICompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedAcid-Base Imbalance | Respiratory Acidosis | Respiratory AlkalosisItaly
-
University of California, San FranciscoNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterCompleted
-
424 General Military HospitalTerminated
-
Karolinska InstitutetThe Swedish Society of Medicine; The Swedish Breast Cancer Association (BRO); Swedish Breast Cancer GroupCompleted